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Introduction
In South Africa, human immunodeficiency virus (HIV) 
infection is widespread and HIV-associated Kaposi sarcoma 
is common.1 In sub-Saharan Africa, HIV-associated Kaposi 
sarcoma frequently runs a rapidly progressive course. In the 
absence of highly active antiretroviral therapy (HAART), the 
disease is fatal.1-4 HAART should be the first-line treatment 
for HIV-associated Kaposi sarcoma. This is because in 
the early stage of HIV-associated Kaposi sarcoma, it may 
bring about regression of established lesions and may 
prevent the development of new lesions.2,3,5-7 However, 
HAART alone is frequently ineffective against advanced 
HIV-associated Kaposi sarcoma. In such cases, HAART 
should be supplemented by systemic chemotherapy.2,8,9 
Consequently, it is suggested that patients with extensive 
oral HIV-associated Kaposi sarcoma, or patients in the 
maculopapular stage of oral HIV-associated Kaposi 
sarcoma, should receive chemotherapy in addition to 
HAART. This might prevent or abort the ominous parallel 
development of severe oral HIV-associated Kaposi sarcoma 
with severe facial lymphoedoema.3,4 
There have been previous reports that patients with 
extensive oral HIV-associated Kaposi sarcoma, who 
had not received HAART, died shortly after developing 
facial lymphoedoema.3,4 This paper reports on a patient 
with extensive oral HIV-associated Kaposi sarcoma who 
received HAART, but nevertheless rapidly declined and died 
soon after developing facial lymphoedoema.
Case report
A 33-year-old HIV-seropositive female, 32 weeks pregnant, 
with a CD4 T cell count of 68 x 10 cells/mm3, extensive 
cutaneous and oral HIV-associated Kaposi sarcoma lesions 
and severe lymphoedoema of the face (Figures 1, 2 and 3) 
was referred to the oral medicine clinic at the Medunsa Oral 
Health Centre. 
The patient had been diagnosed with HIV infection at a 
rural clinic five months previously and had started HAART 
(lamivudine, nevirapine and zidovudine) approximately two 
months later. Three weeks or so after starting HAART she 
developed oral and widespread cutaneous lesions that 
were diagnosed clinically and histopathologically as Kaposi 
Abstract 
Rapidly progressive facial lymphoedoema that develops concurrently with or immediately after rapid enlargement of oral 
Kaposi sarcoma in human immunodeficiency virus (HIV) -seropositive persons forebodes death. Previously, we reported on 
three patients with HIV-associated Kaposi sarcoma who had not been exposed to highly active antiretroviral therapy (HAART) 
and had extensive oral HIV-associated Kaposi sarcoma and rapidly increasing facial lymphoedoema. They died within three 
weeks of developing facial lymphoedoema. We present a similar case of an HIV-seropositive patient with extensive oral 
Kaposi sarcoma and associated facial lymphoedoema. She died three weeks after developing facial lymphoedoema. In 
contrast to our other previously reported cases, this patient had been on HAART for three months before she died. In light 
of this, we implore medical colleagues to treat patients with oral HIV-associated Kaposi sarcoma with HAART during the 
early maculopapular stage of Kaposi sarcoma. If the oral Kaposi sarcoma does not respond, as would be evident by the 
regression or disappearance of the lesions, then systemic chemotherapy should be added promptly, in order to prevent or 
delay the development of extensive exophytic oral lesions with facial lymphoedoema. These appear to be indicative of a 
very poor prognosis.
 Peer reviewed. (Submitted: 2012-02-14. Accepted: 2012-04-19.) © SAAFP  S Afr Fam Pract 2012;54(6):545-547
Advanced oral HIV-associated Kaposi sarcoma with facial 
lymphoedoema as an indicator of poor prognosis
Feller L, DMD, MDent, Head of Department; Essop R, BCom, BChD, Part-Time Lecturer 
Department of Periodontology and Oral Medicine, School of Oral Health Sciences, Faculty of Health Sciences, University of Limpopo, Medunsa Campus
Motswaledi MH, MBChB, MMed, FCDerm(SA), Head of Department
Department of Dermatology, Faculty of Health Sciences, University of Limpopo, Medunsa Campus
Khammissa RAG, BChD, PDD, MSc(Dent), Registrar 
Lemmer J, BDS, HDipDent, FCD(SA)OMP, FCMSAae, HonFCMSA
Honorary Professor, Department of Periodontology and Oral Medicine, University of Limpopo, Medunsa Campus
Professor Emeritus, Oral Medicine and Periodontology, University of Witwatersrand
Correspondence to: Liviu Feller, e-mail: lfeller@ul.ac.za
Keywords: Kaposi sarcoma, oral HIV-Kaposi sarcoma, facial lymphoedoema
Case Study: Advanced oral HIV-associated Kaposi sarcoma with facial lymphoedoema as an indicator of poor prognosis
546 Vol 54 No 6S Afr Fam Pract 2012
Case Study: Advanced oral HIV-associated Kaposi sarcoma with facial lymphoedoema as an indicator of poor prognosis
sarcoma. Despite being on HAART, the cutaneous and oral 
lesions became progressively worse.
Approximately one week prior to our examination, she 
developed rapidly increasing facial lymphoedoema. On oral 
examination, the Kaposi sarcoma lesions were seen on the 
maxillary and mandibular gingivae and on the hard palate. 
The patient was in pain, could not eat and had difficulty 
speaking. In addition to the facial HIV-associated Kaposi 
sarcoma lesions, a Kaposi sarcoma lesion obstructed the 
external auditory meatus (Figure 3). Other symptoms were 
severe anaemia, marked thrombocytopenia, lymphopenia 
and neutrophilia.
A week after our examination, the patient’s seven-week 
premature baby was delivered by a Caesarean section. 
A week later, while systemic investigations were still in 
progress and before cytotoxic chemotherapy could be 
initiated, the patient died.
Discussion
Our patient had extensive cutaneous and oral lesions 
of HIV-associated Kaposi sarcoma and severe facial 
lymphoedoema. We had no access to her medical records 
so it was not possible to determine whether or not her HIV-
associated Kaposi sarcoma was an immune-reconstitution 
inflammatory syndrome.
Extensive oral lesions and lymphoedoema are common 
features of advanced HIV-associated Kaposi sarcoma and 
are associated with poor prognosis.3,4,10 Oral HIV-associated 
Kaposi sarcoma harbours a higher human herpes virus-8 
(HHV-8) load than cutaneous HIV-associated Kaposi 
sarcoma.11 Also, advanced exophytic oral HIV-associated 
Kaposi sarcoma lesions carry a higher HHV-8 load than early 
maculopapular oral lesions.4,10,11 Therefore, it is probable 
that the high HHV-8 burden in advanced oral lesions with 
associated cytokine dysregulation promotes proliferation of 
regional lymphatic endothelial cells and impairs lymphatic 
drainage, with consequent leakage of protein-rich fluid into 
the facial interstitial spaces. This leads to the development 
of facial lymphoedoema.3,4 
It is uncertain whether extensive oral HIV-associated Kaposi 
sarcoma and facial lymphoedoema directly cause death, or 
Figure 1: Extensive cutaneous HIV-associated Kaposi sarcoma 
lesions and severe lymphoedoema of the face Figure 3: HIV-associated Kaposi sarcoma lesions of the right ear
Figure 2: Because of the widespread oral HIV-associated Kaposi 
sarcoma lesions and facial lymphoedoema, the patient could not open 
her mouth to show the extent of the oral lesions
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whether they are merely clinical features that are associated 
with severe immunosuppression and terminal illness. 
Although the death of our HIV-seropositive patient who 
was on HAART may or may not have been owing to HIV-
associated Kaposi sarcoma, the concurrent progression 
of her oral HIV-associated Kaposi sarcoma and her facial 
lymphoedoema certainly preceded her death.
It is evident that patients with advanced HIV-associated 
Kaposi sarcoma survive longer if they take HAART in 
combination with anti-Kaposi sarcoma chemotherapy, 
than if they are on HAART alone.8,12 It is also apparent that 
chemotherapy brings palliative benefits to these patients.9 
Therefore, it is strongly recommended that advanced oral 
HIV-associated Kaposi sarcoma should be treated urgently 
with systemic chemotherapy, in addition to HAART,2,8,9 in the 
hope that regression of the oral lesions will result and that 
facial lymphoedoema, with its ominous implications, may 
be avoided. 
Furthermore, it may be prudent to treat the early maculo-
papular stage of oral HIV-associated Kaposi sarcoma with 
antiretroviral drugs and systemic chemotherapy in order to 
prevent or delay the development of extensive exophytic 
oral lesions and the subsequent facial lymphoedoema, 
which seems to be an indicator of a poor prognosis.3,4,10 
For this reason, in South Africa, where the prevalence of 
HIV infection is high, and where oral HIV-associated Kaposi 
sarcoma is common13 and the likelihood of developing 
associated facial lymphoedoema is considerable, regional 
healthcare facilities should develop a policy to administer 
chemotherapy to patients with advanced HIV-associated 
Kaposi sarcoma. The effects should be monitored. 
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